EDMONTON, May 16 /CNW/ - Biomira Inc. (Nasdaq:BIOM) (TSX:BRA) today
announced that it will web cast its Annual General meeting tomorrow morning at
11:00 a.m. EDT.
Dr. Alex McPherson, Biomira's President and CEO will review:
- Last year's highlights, including, the progress and latest update
on STIMUVAX(R), the Company's lead product candidate for non small
cell lung cancer and its amended arrangements with collaboration
partner, Merck KGaA of Darmstadt, Germany
- Plans for broadening Biomira's pipeline and leveraging its
Synthetic Biologics Business Unit to explore out-licensing
opportunities
- Next steps on its follow-on vaccine, BGLP40
- Business development opportunities
The meeting will take place at the Delta Edmonton South Hotel, Edmonton,
Alberta, Canada.
Web Cast Details
To listen to the live web cast of the President's address please log on
at approximately 11:10 a.m. EDT to:
http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID(equal sign)1401400.
You will be held in queue until Dr. McPherson's presentation commences,
following the business portion of the meeting. A very limited number of
telephone lines are available for those without internet access. Participant
numbers are 1-800-814-4862 or 1-416-644-3430. Conference replay is available
for 48 hours following the meeting and will be available at approximately
2:30 p.m. EDT. The dial in numbers are 1-416-640-1917 or 1-877-289-8525. The
passcode is 21182498 followed by the number sign.
Biomira
Biomira is a biotechnology company specializing in the development of
innovative therapeutic approaches to cancer management. Biomira's commitment
to the treatment of cancer currently focuses on the development of synthetic
vaccines and novel strategies for cancer immunotherapy. We are The Cancer
Vaccine People(TM).
Except for historical information contained herein, this release contains
forward-looking statements that are subject to risks and uncertainties that
may cause actual results to differ materially from the results discussed in
the forward-looking statements, particularly those risks and uncertainties
surrounding Stimuvax(R) to treat men and women with NSCLC, which may include
risks and uncertainties inherent in the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics. Factors that may cause such a difference include the risk that
additional trials may not demonstrate the safety and efficacy required to
satisfy the regulatory authorities, and other matters required to bringing
products to market; dependence on the efforts of third parties, including
suppliers and collaborators, dependence on intellectual property rights and
the effectiveness thereof, difficulties or delays in manufacturing products,
and regulatory developments involving products and manufacturing facilities.
For more detailed information on the risks and uncertainties associated with
the Company's product candidates and other activities see the Company's
periodic reports filed with the applicable securities regulatory authorities
in Canada and the United States Securities and Exchange Commission. The
Company assumes no obligation to update any forward-looking statements.
